Daily Costs and Cost Effectiveness of Glaucoma Fixed Combinations in China
Background. The aim of this study was to compare the daily costs and cost effectiveness of fixed combination glaucoma drugs in China. Methods. This study included the following fixed combination drugs: brinzolamide 1% and timolol 0.5% (Azarga; Alcon, Inc., Fort Worth, TX, USA), travoprost 0.004% and...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2020/2406783 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849691430745800704 |
|---|---|
| author | Chenjia Xu Ruru Guo Dandan Huang Jian Ji Wei Liu |
| author_facet | Chenjia Xu Ruru Guo Dandan Huang Jian Ji Wei Liu |
| author_sort | Chenjia Xu |
| collection | DOAJ |
| description | Background. The aim of this study was to compare the daily costs and cost effectiveness of fixed combination glaucoma drugs in China. Methods. This study included the following fixed combination drugs: brinzolamide 1% and timolol 0.5% (Azarga; Alcon, Inc., Fort Worth, TX, USA), travoprost 0.004% and timolol 0.5% (DuoTrav; Alcon, Inc.), bimatoprost 0.03% and timolol 0.5% (Ganfort; Allergan, Inc., Dublin, Ireland), and latanoprost 0.005% and timolol 0.5% (Xalacom; Pfizer, Inc., New York, NY, USA). Five bottles of each drug were measured. The mean actual volume, mean actual number of drops, volume per drop, daily cost, yearly cost, and per mmHg reduction cost for each drug were calculated. Results. The volumes per drop ranged from 32.61 ± 2.90 μl (DuoTrav) to 24.38 ± 0.23 μl (Ganfort). The number of usage days per bottle varied from 36 days (DuoTrav) to 61 days (Ganfort). Azarga had the lowest daily cost ($0.23) and yearly cost ($84.72), while DuoTrav had the highest daily cost ($0.79) and yearly cost ($287.02). Azarga costed $2.17–$3.30 per mmHg intraocular pressure reduction, which was lower than the other three drugs. For the prostaglandin and ß-adrenergic blocker FCs, Ganfort had the lowest daily cost ($0.35) and per mmHg reduction cost (from $3.40 to $4.04). Conclusions. The daily costs of these drugs were significantly different, with Azarga having the lowest daily cost and best cost effectiveness. For the prostaglandin and β-adrenergic blocker fixed combinations, Ganfort was the most economical choice with its lower daily cost and per mmHg reduction cost. The results of this study could provide drug selection guidance from an economic perspective, but various factors should be considered when making a decision. |
| format | Article |
| id | doaj-art-e7ca523a694142fab265ec2169632a67 |
| institution | DOAJ |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-e7ca523a694142fab265ec2169632a672025-08-20T03:21:02ZengWileyJournal of Ophthalmology2090-004X2090-00582020-01-01202010.1155/2020/24067832406783Daily Costs and Cost Effectiveness of Glaucoma Fixed Combinations in ChinaChenjia Xu0Ruru Guo1Dandan Huang2Jian Ji3Wei Liu4Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin International Joint Research and Development Centre of Ophthalmology and Vision Science, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin 300384, ChinaTianjin Key Laboratory of Retinal Functions and Diseases, Tianjin International Joint Research and Development Centre of Ophthalmology and Vision Science, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin 300384, ChinaTianjin Key Laboratory of Retinal Functions and Diseases, Tianjin International Joint Research and Development Centre of Ophthalmology and Vision Science, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin 300384, ChinaTianjin Key Laboratory of Retinal Functions and Diseases, Tianjin International Joint Research and Development Centre of Ophthalmology and Vision Science, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin 300384, ChinaTianjin Key Laboratory of Retinal Functions and Diseases, Tianjin International Joint Research and Development Centre of Ophthalmology and Vision Science, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin 300384, ChinaBackground. The aim of this study was to compare the daily costs and cost effectiveness of fixed combination glaucoma drugs in China. Methods. This study included the following fixed combination drugs: brinzolamide 1% and timolol 0.5% (Azarga; Alcon, Inc., Fort Worth, TX, USA), travoprost 0.004% and timolol 0.5% (DuoTrav; Alcon, Inc.), bimatoprost 0.03% and timolol 0.5% (Ganfort; Allergan, Inc., Dublin, Ireland), and latanoprost 0.005% and timolol 0.5% (Xalacom; Pfizer, Inc., New York, NY, USA). Five bottles of each drug were measured. The mean actual volume, mean actual number of drops, volume per drop, daily cost, yearly cost, and per mmHg reduction cost for each drug were calculated. Results. The volumes per drop ranged from 32.61 ± 2.90 μl (DuoTrav) to 24.38 ± 0.23 μl (Ganfort). The number of usage days per bottle varied from 36 days (DuoTrav) to 61 days (Ganfort). Azarga had the lowest daily cost ($0.23) and yearly cost ($84.72), while DuoTrav had the highest daily cost ($0.79) and yearly cost ($287.02). Azarga costed $2.17–$3.30 per mmHg intraocular pressure reduction, which was lower than the other three drugs. For the prostaglandin and ß-adrenergic blocker FCs, Ganfort had the lowest daily cost ($0.35) and per mmHg reduction cost (from $3.40 to $4.04). Conclusions. The daily costs of these drugs were significantly different, with Azarga having the lowest daily cost and best cost effectiveness. For the prostaglandin and β-adrenergic blocker fixed combinations, Ganfort was the most economical choice with its lower daily cost and per mmHg reduction cost. The results of this study could provide drug selection guidance from an economic perspective, but various factors should be considered when making a decision.http://dx.doi.org/10.1155/2020/2406783 |
| spellingShingle | Chenjia Xu Ruru Guo Dandan Huang Jian Ji Wei Liu Daily Costs and Cost Effectiveness of Glaucoma Fixed Combinations in China Journal of Ophthalmology |
| title | Daily Costs and Cost Effectiveness of Glaucoma Fixed Combinations in China |
| title_full | Daily Costs and Cost Effectiveness of Glaucoma Fixed Combinations in China |
| title_fullStr | Daily Costs and Cost Effectiveness of Glaucoma Fixed Combinations in China |
| title_full_unstemmed | Daily Costs and Cost Effectiveness of Glaucoma Fixed Combinations in China |
| title_short | Daily Costs and Cost Effectiveness of Glaucoma Fixed Combinations in China |
| title_sort | daily costs and cost effectiveness of glaucoma fixed combinations in china |
| url | http://dx.doi.org/10.1155/2020/2406783 |
| work_keys_str_mv | AT chenjiaxu dailycostsandcosteffectivenessofglaucomafixedcombinationsinchina AT ruruguo dailycostsandcosteffectivenessofglaucomafixedcombinationsinchina AT dandanhuang dailycostsandcosteffectivenessofglaucomafixedcombinationsinchina AT jianji dailycostsandcosteffectivenessofglaucomafixedcombinationsinchina AT weiliu dailycostsandcosteffectivenessofglaucomafixedcombinationsinchina |